Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rathbones H1 underlying profits dip, announces £50m share buyback

(Sharecast News) - Wealth manager Rathbones Group said on Wednesday that H1 profits and margins had dipped, with net outflows and market volatility weighing on performance. Rathbones said underlying pre-tax profits had slipped 4% to £107.7m, while operating margins narrowed to 24.0% from 25.1%. Net outflows totalled £1.0bn, driven by client migration linked to the recent Investec Wealth & Investment integration, though flows improved markedly in Q2, reducing to £200m.

Funds under management and administration held steady at £109.0bn, supported by positive market performance, while statutory pre-tax profits fell to £62.3m, impacted by £45.4m in amortisation and integration costs.

Despite the softer start to FY25, Rathbones reaffirmed its FY guidance, supported by a stronger starting funds under management position in H2 and increasing synergy benefits, and announced its first-ever share buyback of up to £50m, alongside a 3.3% dividend hike to 31.0p per share.

CEO Paul Stockton said: "These results mark a turning point since the combination and enable the business to shift its focus from migration to the future opportunity ahead. Rathbones enters the second half of 2025 in a position of financial strength. We maintain our progressive dividend policy, and announce today our intention to return surplus capital to shareholders through our first-ever share buyback of up to £50.0m."

As of 0925 BST, Rathbones shares were up 0.75% at 1,878.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.